Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Spectral Medical Inc.
  6. Summary
    EDT   CA8475771033

SPECTRAL MEDICAL INC.

(EDT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
01/24/2022 01/25/2022 01/26/2022 01/27/2022 01/28/2022 Date
0.27(c) 0.27(c) 0.27(c) 0.275(c) 0.265(c) Last
78 064 21 647 36 520 2 243 249 673 Volume
-3.57% 0.00% 0.00% +1.85% -3.64% Change
More quotes
Estimated financial data (e)
Sales 2021 2,00 M 1,57 M 1,57 M
Net income 2021 -8,70 M -6,81 M -6,81 M
Net Debt 2021 - - -
P/E ratio 2021 -8,83x
Yield 2021 -
Sales 2022 4,50 M 3,52 M 3,52 M
Net income 2022 -11,5 M -9,00 M -9,00 M
Net Debt 2022 - - -
P/E ratio 2022 -6,63x
Yield 2022 -
Capitalization 71,0 M 55,6 M 55,6 M
Capi. / Sales 2021 35,5x
Capi. / Sales 2022 15,8x
Nbr of Employees 29
Free-Float -
More Financials
Company
Spectral Medical Inc. is a late stage theranostic company that is focused on advancing therapeutic options for sepsis and septic shock. The Company has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada... 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Ratings of Spectral Medical Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SPECTRAL MEDICAL INC.
2021Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2..
GL
2021Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Lates..
AQ
2021Spectral Medical Inc. Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to..
CI
2021Spectral Medical Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to Expa..
AQ
2021Spectral to Present at the Q4 Investor Summit on November 16th
NE
2021Spectral Medical Reports Q3 Results, Provides Corporate Update
MT
2021Spectral Announces Third Quarter Results and Provides Corporate Update
AQ
2021Spectral Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
2021SPECTRAL MEDICAL : to Present at the Benzinga Global Small Cap Conference on October 27, 2..
AQ
2021SPECTRAL MEDICAL : and Dialco Announce Dr. John Kellum to Be Featured as Keynote Lecturer ..
AQ
2021SPECTRAL MEDICAL : CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day a..
AQ
2021SPECTRAL MEDICAL : CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day a..
AQ
2021SPECTRAL MEDICAL : Announces its Participation at Upcoming Investor Conferences
AQ
2021SPECTRAL MEDICAL : Announces Second Quarter Results and Provides Corporate Update
AQ
2021SPECTRAL MEDICAL : Q2 Loss Per Share Holds Steady Year over Year at $0.01
MT
More news
News in other languages on SPECTRAL MEDICAL INC.
2021Spectral Medical annonce ses résultats du troisième trimestre et fait le point sur l'en..
2021La perte par action de Spectral Medical au deuxième trimestre reste stable par rapport ..
2021Earnings Flash (EDT.TO) SPECTRAL MEDICAL affiche un chiffre d'affaires de 559 000 dolla..
2021Spectral Medical annonce la réorganisation interne de Dialco Medical
2021Spectral Medical fait le point sur l'essai clinique Tigris
More news
Chart SPECTRAL MEDICAL INC.
Duration : Period :
Spectral Medical Inc. Technical Analysis Chart | EDT | CA8475771033 | MarketScreener
Technical analysis trends SPECTRAL MEDICAL INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,27 CAD
Average target price 2,40 CAD
Spread / Average Target 806%
EPS Revisions
Managers and Directors
Chris Seto CEO, COO, Chief Financial Officer & Director
Anthony P. Bihl Independent Non-Executive Chairman
Debra M. Foster Vice President-Clinical Development
John Kellum Chief Medical Officer
William Stevens Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SPECTRAL MEDICAL INC.20.45%56
JOHNSON & JOHNSON0.42%452 254
ROCHE HOLDING AG-6.24%308 691
PFIZER, INC.-7.99%304 947
ABBVIE INC.1.86%243 826
ELI LILLY AND COMPANY-11.27%222 206